Disproportionate increase in COPD exacerbation risk for three months after discontinuing LAMA. - Amsterdam 2025

Breathing new life into COPD care: novel data on inhaled therapies

Chair(s): Zsófia Lázár, Thapas Nagarajan

Session type: Poster session

Disproportionate increase in COPD exacerbation risk for three months after discontinuing LAMA.

Alexander Mathioudakis

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Real-World Effectiveness of an Extrafine Triple Therapy with Beclometasone Dipropionate, Formoterol, and Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease

Luca Di Palma

Poster

Abstract

Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 12 months; the RECORD study

Henrik Watz

Poster

Abstract

One-year efficacy of single-inhaler triple inhaled therapy in COPD patients with FEV1 less than 1 L.

Bruno Bodini

Abstract

Effect of tiotropium bromide on TNF - a level: Results from 30-days study in moderate COPD patients.

Mariana Kulynych-miskiv

Poster

Abstract

The TRITRIAL study: the improvement of CAT according to COPD severity

Francesco Macagno

Poster

Abstract

Effectiveness of extrafine single-inhaler triple therapy (efSITT) on asthma control one year post treatment stratified by patients smoking status: the TRIANGLE study

Aliki Korkontzelou

Poster

Abstract

Patient reported improvement in dyspnea and physical inactivity with Budesonide/Glycopyrronium/Formoterol (BGF): AIR-FORCE*study

Saiprasad Patil

Poster

Abstract

Effectiveness and safety of Budesonide/Glycopyrronium/Formoterol (BGF) in severe to very severe airflow obstruction in COPD: sub-group analysis of AIR-FORCE*study

Hanmant Barkate

Poster

Abstract

Evaluation of patient reported outcomes & satisfaction with Budesonide/Glycopyrronium/Formoterol (BGF) in COPD: AIR-FORCE*study

Hanmant Barkate

Poster

Abstract

Impact of dry powder Beclometasone/Formoterol/Glycopyrronium Extrafine Single Inhaler Triple Therapy (efSITT) in patients with Chronic Obstructive Pulmonary Disease (COPD): TriNEXT Study

Capucine Morelot-panzini

Poster

Abstract

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease[ACHIEVE]

Hyesoo Kim

Poster

Abstract

The effect of previous treatment with MITT vs SITT on CAT score after 12-month treatment with efSITT: TRITRIAL study

Francesco Macagno

Poster

Abstract

Investigating individual effects of ICS on COPD exacerbations with causal machine learning

Helene Huts

Poster

Abstract

Causal machine learning to investigate heterogeneity in time to first COPD exacerbation for ICS/LABA versus LAMA/LABA

Helene Huts

Poster

Abstract

Real-life effectiveness of aclidinium/formoterol in COPD control: preliminary results of the REDACT observational study

Konstantinos Kostikas

Poster

Abstract

Real-world effectiveness of beclomethasone/formoterol/glycopyrronium dry powder inhaler Hungarian results of the RESPONSE study

Viktória Dulai

Poster

Abstract

Real-world novel adverse drug reactions (ADRs) associated with indacaterol

James Michael Ramsahai

Poster

Abstract

Clinical and patient-reported outcomes of COPD patients after 12 weeks of treatment with Budesonide/Glycopyrronium/Formoterol: interim analysis of the CHOROS ORION real-life study in Italy

Micaela Romagnoli

Poster

Abstract

Disproportionate increase in COPD exacerbation risk for three months after discontinuing LAMA.

Alexander Mathioudakis

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}